keyword
https://read.qxmd.com/read/38652570/brentuximab-vedotin-for-skin-involvement-in-refractory-diffuse-cutaneous-systemic-sclerosis-an-open-label-trial
#1
JOURNAL ARTICLE
Andreu Fernández-Codina, Tatiana Nevskaya, Murray Baron, C Thomas Appleton, Matthew J Cecchini, Amanda Philip, Maha El-Shimy, Louise Vanderhoek, Iago Pinal-Fernández, Janet E Pope
OBJECTIVE: We explored the efficacy and safety of brentuximab vedotin, a chimeric anti-CD30 antibody drug conjugate, in patients with severe active diffuse cutaneous systemic sclerosis (dcSSc). METHODS: This phase II proof-of-concept, single center, open-label, single arm, investigator-initiated trial included patients ≥18 years, with dcSSc, modified Rodnan skin score (mRSS) ≥15 with <5 years since the first non-Raynaud's symptom and/or skin worsening despite immunosuppression who were treated with intravenous brentuximab vedotin 0...
April 23, 2024: Rheumatology
https://read.qxmd.com/read/38646529/case-report-a-rare-immune-related-adverse-effect-hepatic-cavernous-hemangioma-induced-by-camrelizumab
#2
Chuantao Zhang, Guanqun Wang, Ning Liu, Tianjun Li, Jingjuan Zhu, Helei Hou
BACKGROUND: Camrelizumab, a programmed death 1 (PD-1) inhibiting antibody, has demonstrated efficacy in various malignancies and received approval in multiple countries. Despite its therapeutic benefits, camrelizumab is associated with a unique spectrum of immune-related adverse effects (irAEs), predominantly reactive cutaneous capillary endothelial proliferation (RCCEP). However, visceral manifestations of such endothelial proliferations, particularly hepatic cavernous hemangiomas, have not been extensively documented...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38645875/emerging-insights-into-stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-induced-by-immune-checkpoint-inhibitor-and-tumor-targeted-therapy
#3
JOURNAL ARTICLE
Min Lin, Ting Gong, Shifan Ruan, Xiaoqing Lv, Rongying Chen, Xinhong Su, Bo Cheng, Chao Ji
OBJECTIVE: Anticancer drugs have revolutionized tumor therapy, with cutaneous toxicities such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) being common immune-related adverse events. The debate over the efficacy of systemic corticosteroids in treating these conditions persists, while tumor necrosis factor (TNF)-alpha inhibitors show promise. This study aims to evaluate the effectiveness and safety of combination therapy involving the TNF-α inhibitor adalimumab for SJS/TEN induced by anticancer drugs...
2024: Journal of Inflammation Research
https://read.qxmd.com/read/38639526/the-combination-of-hyaluronic-acid-and-collagenase-in-the-treatment-of-skin-ulcers-an-open-multicenter-clinical-study-assessing-safety-and-tolerability-of-bionect-start%C3%A2
#4
JOURNAL ARTICLE
P Fino, C Chello, C Latini, S Occhionorelli, M Moruzzi, N Scuderi, G Pellacani
OBJECTIVE: Several clinical studies have shown that hyaluronic acid collagenase is well-tolerated and very effective in managing chronic venous ulcers. The aim of the present study is to confirm the safety and tolerability of daily application in patients suffering from cutaneous ulcers of different etiologies. The efficacy of the treatment and its impact on patients' quality of life are also assessed. PATIENTS AND METHODS: Patients with a clinical diagnosis of skin ulcer with devitalized/fibrinous/slough tissue that could delay the healing process were enrolled in the study...
April 2024: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/38639452/dupilumab-as-effective-therapy-for-corticosteroid-dependent-resistant-type-2-inflammation-related-cutaneous-adverse-reactions
#5
JOURNAL ARTICLE
C Shen, N Wu, L Yang, B Wang, T Liu, J Tao
No abstract text is available yet for this article.
April 2024: Journal of Investigational Allergology & Clinical Immunology
https://read.qxmd.com/read/38634840/trips-through-the-skin-reviewing-cutaneous-drug-reactions-to-psychedelics-and-hallucinogens
#6
REVIEW
Syed Minhaj Rahman, Yousef Salem, Aamir Hussain
<u> <i/> </u>Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly characterized. This review characterizes the cutaneous reactions associated with psychedelic and hallucinogenic drugs. A review of PubMed and Scopus was conducted from the inception of databases to August 31, 2023. Search terms included drug names and classes (cannabis, MDMA, ecstasy, 3,4-methylenedioxymethamphetamine, psychedelics, hallucinogens, peyote, marijuana, lysergic acid diethylamide, LSD, ketamine, dimethyltryptamine, DMT, phencyclidine, PCP, dextromethorphan, psilocybin, and ayahuasca), and dermatosis terms (dermatitis, contact dermatitis, drug eruption, skin reaction, and urticaria)...
April 17, 2024: Dermatitis
https://read.qxmd.com/read/38618248/antibody-platinum-iv-prodrugs-conjugates-for-targeted-treatment-of-cutaneous-squamous-cell-carcinoma
#7
JOURNAL ARTICLE
Xiangye Yin, Yingjie Zhuang, Haiqin Song, Yujian Xu, Fan Zhang, Jianxin Cui, Lei Zhao, Yingjie Yu, Qixu Zhang, Jun Ye, Youbai Chen, Yan Han
Antibody-drug conjugates (ADCs) are a new type of targeting antibodies that conjugate with highly toxic anticancer drugs via chemical linkers to exert high specificity and efficient killing of tumor cells, thereby attracting considerable attention in precise oncology therapy. Cetuximab (Cet) is a typical antibody that offers the benefits of good targeting and safety for individuals with advanced and inoperable cutaneous squamous cell carcinoma (cSCC); however, its anti-tumor activity is limited to a single use...
March 2024: Journal of Pharmaceutical Analysis
https://read.qxmd.com/read/38614940/efficacy-and-safety-of-0-5-colchicine-cream-versus-5-5-fluorouracil-cream-in-the-treatment-of-cutaneous-field-cancerization-a-randomized-clinical-trial
#8
JOURNAL ARTICLE
Amanda Soares Teixeira, Ivanka Miranda de Castro Martins, Anna Carolina Miola, Hélio Amante Miot
BACKGROUND: 5-Fluorouracil (5-FU) is a first-line drug to treat cutaneous field cancerization (CFC). There are few clinical trials with topical colchicine (COL). OBJECTIVE: To evaluate the effectiveness of 0.5% COL cream versus 5% 5-FU cream in the treatment of CFC. METHOD: This was a randomized, open, self-controlled clinical trial. Forty-five patients (90 forearms), with three to ten actinic keratoses (AK) on each forearm, used 0.5% COL cream 2×/day for seven days on one forearm, and 5% 5-FU cream 2× /day, for 21 days, on the other forearm...
April 12, 2024: Anais Brasileiros de Dermatologia
https://read.qxmd.com/read/38605770/antitubercular-drug-induced-lichen-planus-a-case-study-with-a-mini-literature-review
#9
JOURNAL ARTICLE
Sanjana C Shanmukhappa, Winny John, Vineeta Kevalramani, Srivatsa Lokeshwaran, Shireen Furtado, Mahesh Nosenoor
INTRODUCTION: Drug-induced lichen planus is a cutaneous adverse effect that manifests as a systemic eruption of flat-topped, erythematous, or violaceous papules resembling lichen planus on the trunk and extremities. Although antitubercular therapy has been linked to cutaneous hypersensitivity reactions, the literature on such cases is scarce. Here, we present a case to contribute to this field, reporting on its presentation and management, and reviewing previous case studies. CASE REPORT: Our patient, a 63-year-old male, presented with black pigmented patches on the skin, having been diagnosed with pulmonary tuberculosis and on antitubercular therapy for the past two months...
February 2024: Journal of Family Medicine and Primary Care
https://read.qxmd.com/read/38586180/panitumumab-induced-periorbital-dermatitis-a-case-report
#10
Napapat Pongbangpho, Kumutnart Chanprapaph, Wimolsiri Iamsumang
Panitumumab is a recombinant, fully humanized immunoglobulin G2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is approved for the first- and second-line treatment of advanced wild-type KRAS colorectal cancer. Although common cutaneous side effects include acneiform dermatitis, folliculitis, and xerosis, ocular toxicities have occasionally been reported. Herein, we report the case of an 81-year-old Thai female with chemorefractory advanced stage sigmoid colon cancer who developed isolated periorbital dermatitis following treatment with panitumumab plus modified FOLFOX6...
2024: Clinical, Cosmetic and Investigational Dermatology
https://read.qxmd.com/read/38585192/systematic-review-of-intralesional-therapies-for-cutaneous-warts
#11
REVIEW
Sarah A Mullen, Emma L Myers, Rebecca L Brenner, Kim T Nguyen, Tara A Harper, Darby Welsh, Storm Keffer, Jenna Mueller, Melodi Javid Whitley
Intralesional therapies are used for recalcitrant warts, but no Food and Drug Administration-approved treatment exists nor is there consensus regarding the most efficacious therapy. Therefore, this systematic review aims to summarize efficacy and adverse events reported in 62 randomized controlled trials (RCTs) of intralesional therapies for cutaneous warts. The most studied intralesional therapies included measles, mumps, rubella (MMR) vaccine (n = 24 studies), purified protein derivative (PPD) (n = 19 studies), vitamin D3 (n = 15 studies), and Candida antigen (n = 14 studies)...
May 2024: JID innovations
https://read.qxmd.com/read/38570725/dutch-pharmacogenetics-working-group-dpwg-guideline-for-the-gene-drug-interaction-of-cyp2c9-hla-a-and-hla-b-with-anti-epileptic-drugs
#12
JOURNAL ARTICLE
Lisanne E N Manson, Marga Nijenhuis, Bianca Soree, Nienke J de Boer-Veger, Anne-Marie Buunk, Elisa J F Houwink, Arne Risselada, Gerard A P J M Rongen, Ron H N van Schaik, Jesse J Swen, Daan J Touw, Roos van Westrhenen, Vera H M Deneer, Henk-Jan Guchelaar
By developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy, the Dutch Pharmacogenetics Working Group (DPWG) aims to advance the implementation of pharmacogenetics (PGx). This guideline outlines the gene-drug interaction of CYP2C9 and HLA-B with phenytoin, HLA-A and HLA-B with carbamazepine and HLA-B with oxcarbazepine and lamotrigine. A systematic review was performed and pharmacotherapeutic recommendations were developed. For CYP2C9 intermediate and poor metabolisers, the DPWG recommends lowering the daily dose of phenytoin and adjust based on effect and serum concentration after 7-10 days...
April 3, 2024: European Journal of Human Genetics: EJHG
https://read.qxmd.com/read/38569738/severe-insulin-resistance-in-a-patient-with-diabetes-after-treatment-with-brentuximab-vedotin
#13
JOURNAL ARTICLE
Greet Peeters, Ann Verhaegen
A man in his late 60s with a history of well-controlled type 2 diabetes and hepatic cirrhosis presented to the emergency department due to uncontrollable hyperglycaemia following the initial brentuximab vedotin (BV) infusion. BV was initiated as a treatment for mycosis fungoides, a form of cutaneous T-cell lymphoma. The patient was diagnosed with severe hyperglycaemia with ketosis. Empiric treatment with amoxicillin-clavulanic acid, hydration and intravenous insulin infusion was initiated. Hyperglycaemia persisted despite receiving massive amounts of insulin and was corrected only after treatment with high-dose methylprednisolone for suspected type B insulin resistance...
April 2, 2024: BMJ Case Reports
https://read.qxmd.com/read/38568509/human-leukocyte-antigens-and-sulfamethoxazole-cotrimoxazole-induced-severe-cutaneous-adverse-reactions-a-systematic-review-and-meta-analysis
#14
JOURNAL ARTICLE
Po-Chien Wu, Wei-Ti Chen, I-Hsin Huang, Chun-Bing Chen, Chuang-Wei Wang, Cheng-Chen Tai, Wen-Hung Chung, Ching-Chi Chi
IMPORTANCE: Sulfamethoxazole (SMX) and cotrimoxazole (CTX), a fixed-dose combination of SMX and trimethoprim in a 5:1 ratio, are antibacterial sulfonamides commonly used for treating various diseases. A substantial prevalence of severe cutaneous adverse reactions (SCARs) following the administration of these drugs has been reported. However, the association between human leukocyte antigen (HLA) genotypes and SMX/CTX-induced SCARs has remained unclear. OBJECTIVE: To investigate the association between HLA genotypes and SMX/CTX-induced SCARs...
April 3, 2024: JAMA Dermatology
https://read.qxmd.com/read/38564381/functional-and-cutaneous-treatment-outcomes-with-intravenous-immunoglobulin-for-eosinophilic-fasciitis-a-retrospective-study
#15
JOURNAL ARTICLE
Bianca Obiakor, Winnie Fan, Rebecca Jacobson, Jocelyn Gandelman, Anna Haemel
BACKGROUND: Eosinophilic fasciitis (EF) is a rare subtype of deep morphea with an elevated risk of functional impairment. No treatment algorithm has been established for adults with EF refractory to traditional corticosteroid or immunomodulatory treatments. Research on cutaneous and functional outcomes of alternative therapies, such as intravenous immunoglobulin (IVIG), remains scarce.&nbsp; Objective: To describe the functional and cutaneous outcomes associated with IVIG in adults with treatment-refractory EF at a tertiary referral center...
April 1, 2024: Journal of Drugs in Dermatology: JDD
https://read.qxmd.com/read/38542870/selectivity-studies-and-free-energy-calculations-of-akt-inhibitors
#16
JOURNAL ARTICLE
Haizhen A Zhong, David T Goodwin
Protein kinase B (PKB) or AKT protein is an important target for cancer treatment. Significant advances have been made in developing ATP-competitive inhibitors and allosteric binders targeting AKT1. However, adverse effects or toxicities have been found, and the cutaneous toxicity was found to be linked to the inhibition of AKT2. Thus, selective inhibition of AKT inhibitors is of significance. Our work, using the Schrödinger Covalent Dock (CovDock) program and the Movable Type (MT)-based free energy calculation (ΔG), yielded small mean errors for the experimentally derived binding free energy (ΔG)...
March 10, 2024: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/38534996/novel-strategy-in-the-detection-of-adverse-cutaneous-drug-reactions-a-case-series-study
#17
JOURNAL ARTICLE
Erika-Gyöngyi Bán, Patrick Lechsner, Eszter-Anna Dho-Nagy, Maria-Antonia Balan, István Major-Szakács, Attila Brassai, Zsuzsánna Simon-Szabó, Corina Ureche
With multimorbidity on the rise, adverse cutaneous drug reactions are becoming a daily challenge in clinical practice. The objective evaluation of the skin lesion is crucial but hardly realized due to missing technology and guidelines. In this study, the novel Dermus SkinScanner-U, an optically guided high-frequency ultrasound imaging device, was evaluated regarding its comparability with the Dermatology Life Quality Index (DLQI) and the pharmacological analysis of the patients' drug therapy. A total of 40 adult patients were evaluated, all with chronic medication use and skin lesions that led to non-compliance toward the pharmacotherapy...
March 7, 2024: Diagnostics
https://read.qxmd.com/read/38534679/the-application-of-knowledge-based-clinical-decision-support-systems-to-detect-antibiotic-allergy
#18
JOURNAL ARTICLE
Nayoung Han, Ock Hee Oh, John Oh, Yoomi Kim, Younghee Lee, Won Chul Cha, Yun Mi Yu
Prevention of drug allergies is important for patient safety. The objective of this study was to evaluate the outcomes of antibiotic allergy-checking clinical decision support system (CDSS), K-CDSTM . A retrospective chart review study was performed in 29 hospitals and antibiotic allergy alerts data were collected from May to August 2022. A total of 15,535 allergy alert cases from 1586 patients were reviewed. The most frequently prescribed antibiotics were cephalosporins (48.5%), and there were more alerts of potential cross-reactivity between beta-lactam antibiotics than between antibiotics with the same ingredients or of the same class...
March 7, 2024: Antibiotics
https://read.qxmd.com/read/38532203/topical-application-of-ozonated-sunflower-oil-accelerates-the-healing-of-lesions-of-cutaneous-leishmaniasis-in-mice-under-meglumine-antimoniate-treatment
#19
JOURNAL ARTICLE
Ana Paula Pivotto, Lucas Bonatto de Souza Lima, Alexandra Michelon, Camilla Zottesso Pellon Ferreira, Rinaldo Ferreira Gandra, Thaís Soprani Ayala, Rafael Andrade Menolli
Besides being scarce, the drugs available for treating cutaneous leishmaniasis have many adverse effects. Ozone is an option to enhance the standard treatment due to the wound-healing activity reported in the literature. In this study, we evaluated the efficiency of ozonated sunflower oil as an adjuvant in treating cutaneous lesions caused by Leishmania amazonensis. BALB/c mice were infected with L. amazonensis, and after the lesions appeared, they were treated in four different schedules using the drug treatment with meglumine antimoniate (Glucantime®), with or without ozonated oil...
March 27, 2024: Medical Microbiology and Immunology
https://read.qxmd.com/read/38527223/pityriasiform-drug-eruption-associated-with-venetoclax-for-acute-myeloid-leukaemia
#20
JOURNAL ARTICLE
Timothy J Liu, Erin K McMeniman
Venetoclax is a targeted antileukaemic therapy that has emerged as the primary treatment of acute myeloid leukaemia in patients of advanced age or who would otherwise be ineligible for standard chemotherapy. Despite the documented evidence of cutaneous side effects of venetoclax, few reports have clarified presenting cutaneous features beyond the descriptors 'rash' and 'pruritus'. In this report, we describe the development of a pityriasiform drug eruption following venetoclax-based induction therapy for acute myeloid leukaemia...
March 22, 2024: Anti-cancer Drugs
keyword
keyword
109299
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.